| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. (NBIX) has 17 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. NBIX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 140.4K | $22.44M | - | |
| Other | 56.4K | $9.02M | - | |
| Other | 22.4K | $3.58M | - | |
| Other | 16.2K | $2.59M | -8,433 | |
| Other | 13.3K | $2.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Gorman Kevin Charles55 | Director | Sale+OE | 2,707 | $152.92 | $413,966.89 | -0.5% | -29.8% | -10.4% | |
| Jan 27, 2025 | Gorman Kevin Charles55 | Director | Sale+OE | 146,105 | $149.46 | $21,836,502.65 | -22.1% | -28.2% | -9.6% | |
| Jan 15, 2025 | Gano Kyle54 | Chief Executive Officer | Sale+OE | 65,000 | $141.50 | $9,197,549.84 | -19.4% | -32.5% | -6.5% | |
| Dec 31, 2024 | Delaet Ingrid66 | Chief Regulatory Officer | Sale+OE | 272 | $138.10 | $37,563.20 | -9.8% | -19.0% | +3.9% | |
| Dec 17, 2024 | Delaet Ingrid66 | Chief Regulatory Officer | Sale+OE | 1,091 | $135.00 | $147,285.00 | -30.3% | -18.4% | +3.7% | |
| Nov 29, 2024 | Onyia Jude51 | Chief Scientific Officer | Sale+OE | 2,331 | $126.29 | $294,372.67 | -13.1% | -7.3% | +20.0% | |
| Oct 3, 2024 | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,295 | $113.66 | $147,189.70 | -77.5% | +23.2% | +22.5% | |
| Sep 13, 2024 | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 3,461 | $121.88 | $421,828.06 | -67.4% | +3.7% | +16.0% | |
| Aug 15, 2024 | Rastetter William H48 | Director | Sell | 14,250 | $146.69 | $2,090,332.50 | -27.5% | -15.1% | -10.1% | |
| Aug 13, 2024 | Abernethy Matt57 | Chief Financial Officer | Sale+OE | 14,100 | $150.38 | $2,120,346.72 | -30.9% | -15.6% | -12.7% |